WAVE LIFE SCIENCES LTD. (NASDAQ:WVE) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On July3, 2017, Masaharu Tanaka informed the Board of Directors (the “Board”) of WAVE Life Sciences Ltd. (“WAVE”) that he has decided to retire from the Board and therefore will not be seeking re-election when his term expires at WAVE’s upcoming 2017 Annual General Meeting of Shareholders. Mr.Tanaka’s decision follows his recent retirement from Kagoshima Development Co. Ltd., and he indicated that his decision did not arise from any disagreement on any matter relating to WAVE’s operations, policies or practices.

Mr.Tanaka joined the Board in connection with Kagoshima Shinsangyo Sousei Investment Limited Partnership’s initial investment in WAVE and he helped transition WAVE to become a publicly traded company in 2015. WAVE thanks Mr.Tanaka for his service and contributions to WAVE since August 2014.

About WAVE LIFE SCIENCES LTD. (NASDAQ:WVE)

WAVE Life Sciences Ltd. is a preclinical biopharmaceutical company. The Company focuses on developing its synthetic chemistry platform to develop and commercialize a pipeline of nucleic acid-based therapeutics. It develops nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Its advanced therapeutic programs are in Huntington’s disease, duchenne muscular dystrophy (DMD) and inflammatory bowel disease (IBD). In Huntington’s disease, it has programs that target HTT SNP-1 and HTT SNP-2; in DMD, it targets Exon 51, and in IBD, it targets SMAD7. It has selected lead product candidates in its programs targeting HTT SNP-1 and Exon 51. It has late-stage discovery programs in epidermolysis bullosa simplex, in which it targets KRT14 SNP-1 and KRT14 SNP-2, and in DMD, in which it is focused on an additional DMD target, AcRIIb.